Attovia reports 12-week data from ATTO-1310 itch therapy trial

Attovia Therapeutics (NASDAQ:ATTO) reported 12-week Phase 1b trial results for ATTO-1310, an anti-IL-31 therapy. In chronic pruritus patients, 82% of treated patients saw a 4-point reduction in itch versus 22% with placebo. In high-itch atopic dermatitis patients, 44% of treated patients achieved a 4-point reduction versus 75% with placebo. The drug was generally well-tolerated, with plans for Phase 2 trials in 2027.

Original reporting
Published Nov 5, 2026, 9:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:18 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ATTO
Bullish
high confidence
Mentioned
$ATTO
Relevance
9/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$ATTOBullishHigh
01

Why it matters

The release of Phase 1b data provides the first quantitative efficacy readout, which can materially affect valuation and funding prospects.

02

Market read

First‑time trial data for a micro‑cap biotech often trigger significant price moves, making this a high‑impact news item.

03

What to watch

Potential safety signals and the need for substantial funding to advance to Phase 2 could temper upside.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Attovia Therapeutics (NASDAQ:ATTO) is a clinical‑stage biotech focused on anti‑IL‑31 therapies for chronic itch conditions.

Company-level read

Ticker impact

$ATTOBullishHigh confidence
Context

Attovia Therapeutics released first‑time topline 12‑week Phase 1b data for ATTO‑1310, showing significant itch reduction and IL‑31 suppression.

Expected impact

likely upward pressure as the market prices in the promising trial data

Evidence & confidence

The data are a primary disclosure, showing strong efficacy signals and a clear path to Phase 2, which is material for a micro‑cap biotech.

Market effects

May lift sentiment for other itch‑therapy and IL‑31 targeting biotech firms.

Limited to US‑listed biotech investors.

Modest; primarily relevant to specialty pharma investors.

Counterpoint

Phase 1b data are early; efficacy in larger Phase 2 trials remains uncertain, risk of setbacks.

Key entities

  • Attovia Therapeutics, Inc.

    Developer of ATTO‑1310, an anti‑IL‑31 therapy.

Related articles

$ATTOMed

Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Attovia Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update Announced positive topline 12-week Phase 1b results for ATTO-1310 in patients with chronic pruritus (CP) and high-itch atopic dermatitis (AD) Initiation of global Phase

$ATTOMedAI 8/10

Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials

Attovia Therapeutics (ATTO) reported sustained itch relief in a small study for its drug ATTO-1310, with no serious adverse events related to the treatment. The company plans phase 2 trials with 300 patients in one study and 255 in another, aiming for quarterly maintenance dosing. Attovia expects data from a phase 1b study in 2027 and has a cash runway into 2030. The company is developing antibody-based treatments for immune-mediated and inflammatory diseases.

$ATTOMedAI 8/10

Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update

Attovia Therapeutics, Inc. (ATTO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026 Phase 2 studies of

$ATTOMedAI 8/10

Wall Street analysts bullish on Attovia as itch drug data fuel biotech optimism

Attovia Therapeutics received bullish ratings from Citi, Morgan Stanley, and RBC, with price targets ranging from $30 to $45, citing promising early data for its chronic-itch drug ATTO-1310 and its antibody platform. The stock, trading around $21, has significant upside potential according to analysts. The company has $420M in cash post-IPO, reducing near-term financing concerns. Analysts caution about clinical-stage risks, including trial outcomes and competition.